Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
CONTEXT AND OBJECTIVE: Glucose-dependent insulinotropic polypeptide (GIP) in combination with hyperinsulinemia increases blood flow and triglyceride (TAG) clearance in subcutaneous (sc) abdominal adipose tissue in lean humans. The present experiments were performed to further investigate the role of insulin for the vasoactive effect of GIP in adipose tissue metabolism and whether the vasodilatory effect of GIP is dependent on C-peptide. METHODS: Six lean healthy subjects were studied. The sc abdominal adipose tissue metabolism was assessed by Fick's principle during GIP infusion (1.5 pmol/kg/min) in combination with 1) euglycemic-high insulinemic clamp (Eugluc-Hiinsu), raising plasma insulin concentrations to postprandial levels, 2) hyperglycemic-euinsulinemic clamp (Hygluc-Euinsu), and 3) hyperglycemic-hyperinsulinemic clamp, raising plasma insulin concentrations to supraphysiological levels. During the hyperglycemic clamps, endogenous insulin and C-peptide secretion were inhibited by infusion of the somatostatin analogue octreotide. RESULTS: During GIP infusion, Eugluc-Hiinsu, and hyperglycemic-hyperinsulinemic clamps, sc abdominal adipose tissue blood flow (ATBF) was similar and increased from 2.1 ± 0.2 and 2.2 ± 0.4 ml min(-1) (100 g tissue)(-1) to 7.1 ± 0.6 and 7.6 ± 0.1 ml min(-1) (100 g tissue)(-1), respectively (P < .01). ATBF remained virtually constant (2.7 ± 0.4 ml min(-1) [100 g tissue](-1)) during Hygluc-Euinsu and GIP infusion. In addition, adipose tissue TAG clearance increased significantly (P = .03), whereas free fatty acid output (P = .01), glycerol output (P = .02) and free fatty acid/glycerol release ratio (P = .04) decreased during the Eugluc-Hiinsu clamp compared to Hygluc-Euinsu clamp with GIP. CONCLUSION: In healthy lean humans, insulin is permissive for GIP to induce an increase in blood flow and TAG clearance in sc abdominal adipose tissue. This effect is independent of C-peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accordingly, other research highlighted the insulin-dependent effects of GIP on adipose tissue blood flow and metabolism, through insulin inhibition mediated by the administration of somatostatin [115].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [115]
Citations
Cites
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Lipolysis and lipid mobilization in human adipose tissue
Lafontan, M., & Langin, D. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.05.001 · Cited by 826
Adipose tissue as a buffer for daily lipid flux
Frayn, K. (2002) · Diabetologia · doi:10.1007/s00125-002-0873-y · Cited by 752
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Self-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Self-citationDeacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citationBlood Flow through Human Adipose Tissue Determined with Radioactive Xenon
Larsen, O. A., Lassen, N. A., & Quaade, F. (1966) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1966.tb03208.x · Cited by 337
Magnetic resonance imaging of total body fat
Thomas, E. L., Saeed, N., Hajnal, J. V., Brynes, A., Goldstone, A. P., Frost, G., & Bell, J. D. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.5.1778 · Cited by 313
Johansson, B. L., Sj�berg, S., & Wahren, J. (1992) · Diabetologia · doi:10.1007/bf00402543 · Cited by 196
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
“Moreover, GIP can exert therapeutic benefits beyond its primary incretin role, by improving insulin sensitivity and lipid homeostasis in adipose tissue [8].”
BackgroundNicholls, S. J., Bhatt, D. L., Buse, J. B., Prato, S. D., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Nauck, M. A., Nissen, S. E., Sattar, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.09.007 · Cited by 248
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132
Self-citationPirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab722 · Cited by 113
Thondam, S. K., Cuthbertson, D. J., & Wilding, J. P. H. (2020) · Peptides · doi:10.1016/j.peptides.2019.170208 · Cited by 77
Skov-Jeppesen, K., Svane, M. S., Martinussen, C., Gabe, M. B. N., Gasbjerg, L. S., Veedfald, S., Bojsen-Møller, K. N., Madsbad, S., Holst, J. J., Rosenkilde, M. M., et al. (2019) · Bone · doi:10.1016/j.bone.2019.05.014 · Cited by 75
Self-citationThondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
Self-citationGlucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Yu, X., Chen, S., Funcke, J.-B., Straub, L. G., Pirro, V., Emont, M. P., Droz, B. A., Collins, K. A., Joung, C., Pearson, M. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.003 · Cited by 67
Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
Asmar, A., Asmar, M., Simonsen, L., Madsbad, S., Holst, J. J., Hartmann, B., Sorensen, C. M., & Bülow, J. (2017) · Physiological Reports · doi:10.14814/phy2.13073 · Cited by 41
Self-citationGIP-induced vasodilation in human adipose tissue involves capillary recruitment
Asmar, M., Asmar, A., Simonsen, L., Dela, F., Holst, J. J., & Bülow, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0144 · Cited by 37
Self-citationJiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
Guccio, N., Gribble, F. M., & Reimann, F. (2022) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-062320-113625 · Cited by 36
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue
Kagdi, S., Lyons, S. A., & Beaudry, J. L. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0361 · Cited by 33
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
Irwin, N., Gault, V. A., O’Harte, F. P. M., & Flatt, P. R. (2020) · Peptides · doi:10.1016/j.peptides.2019.170203 · Cited by 27
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Rabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
Skov‐Jeppesen, K., Veedfald, S., Madsbad, S., Holst, J. J., ROSENKILDE, M. M., & Hartmann, B. (2021) · Bone · doi:10.1016/j.bone.2021.116065 · Cited by 24
Self-citationGIP-derived GIP receptor antagonists – a review of their role in GIP receptor pharmacology
ROSENKILDE, M. M., Lindquist, P., Kizilkaya, H. S., & Gasbjerg, L. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171212 · Cited by 22
Roberts‐Thomson, K. M., Parker, L., Betik, A. C., Wadley, G. D., Gatta, P. A. D., Marwick, T. H., & Keske, M. A. (2022) · The Journal of Physiology · doi:10.1113/jp282428 · Cited by 22
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
“Accordingly, other research highlighted the insulin-dependent effects of GIP on adipose tissue blood flow and metabolism, through insulin inhibition mediated by the administration of somatostatin [115].”
BackgroundRasmussen, R. S., Langberg, L. S., Østergaard, F., Nielsen, S. W., Vestergaard, M. B., Skov‐Jeppesen, K., Hartmann, B., Johannesen, H. H., Holst, J. J., Haddock, B., et al. (2025) · Diabetes · doi:10.2337/db25-0149 · Cited by 17
Self-citationMaagensen, H., Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., & Knop, F. K. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00767-2 · Cited by 16
Kushner, P., Anderson, J. E., Simon, J., Boye, K. S., Ranta, K., Torcello-Gómez, A., & Levine, J. A. (2023) · Clinical Diabetes · doi:10.2337/cd22-0029 · Cited by 14
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Yan, R., Liu, L., Tzoulaki, I., Fan, J.-G., Targher, G., Yuan, Z., & Zhao, J. (2024) · Liver International · doi:10.1111/liv.16150 · Cited by 11
Erfanian, S., Mir, H., Abdoli, A., & Roustazadeh, A. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01477-z · Cited by 10
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 9
Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 8
Fan, Y., Yuan, J., Dong, L., Yu, C., Ding, H., Xie, D., Guan, R., Li, R., Zou, W., Long, S., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16203 · Cited by 8
Otsuka, E., Kitamura, M., Funakoshi, S., Mukae, H., & Nishino, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1362242 · Cited by 8
Saari, T., Koffert, J., Honka, H., Kauhanen, S. P., U-Din, M., Wierup, N., Lindqvist, A., Groop, L., Virtanen, K. A., & Nuutila, P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac191 · Cited by 6
GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
Fano, M. D., Haurum, L. L., Andreasen, C. R., Porcellati, F., & Andersen, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70888 · Cited by 5
Metformin Boosts Intestinal Lipid Sensing via GIP to Suppress Feeding
Kuah, R., Wang, M. T., Yang, Z., Back, G., Li, R., Bruce, K., LoChoy, J. N., Beaudry, J. L., Barros, D. R., Zhang, S., et al. (2025) · Diabetes · doi:10.2337/db25-0100 · Cited by 5
Morais, T., Seabra, A. L., Patrício, B. G., Carrageta, D. F., Guimarães, M., Nora, M. C., Oliveira, P. F., Alves, M. G., & Monteiro, M. P. (2023) · Metabolites · doi:10.3390/metabo13050587 · Cited by 5
Xu, Z., Wen, S., Dong, M., & Zhou, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16146 · Cited by 4
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
Safety of native glucose-dependent insulinotropic polypeptide in humans
Helsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171214 · Cited by 3
Guan, T., Zhang, W., Li, M., Wang, Q., Guo, L., Guo, B., Luo, X., Li, Z., Lu, M., Dong, Z., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111615 · Cited by 3
Gradel, A. K. J., Kildegaard, J., Porsgaard, T., Lykkesfeldt, J., & Refsgaard, H. H. F. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13574 · Cited by 2
Sotorník, R., Brassard, P., Ménard, J., Gagnon‐Auger, M., Baillargeon, J., & Ardilouze, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16589 · Cited by 1
Smarkusz-Zarzecka, J., Radziszewska, M., Gofron, K. K., & Ostrowska, L. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10098-7 · Cited by 1
Pearson, M. J., Willency, J. A., Lin, Y., Abadi, A., Hartman, M. L., Coşkun, T., Ruotolo, G., Duffin, K. L., Haupt, A., Newgard, C. B., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag201
Incretin-based therapies: Effects on plasma lipids and potential mechanisms
Syed‐Abdul, M. M., & Lewis, G. F. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109057
Brayner, B., Mason, S. A., Karimi, E., Keske, M. A., Roberts‐Thomson, K. M., Parker, L., Betik, A. C., Thomas, H. J., Way, K. L., Livingstone, K. M., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00028.2026
Asmar, M., Bülow, J., Holst, J. J., & Asmar, A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag084
Self-citationGIP Acutely Blunts Insulin- and GLP-1–Induced Muscle Microvascular Perfusion
Liu, J., Chun, C., Sin, T. K., Zhao, F., Aylor, K. W., Tushi, N. J., Sun, S., & Liu, Z. (2026) · Diabetes · doi:10.2337/db25-1009
Brown and white adipose tissue metabolism in obesity: stimulation by cold and meal ingestion
Saari, T. (2022) · UTUPub (University of Turku)
Zhang, Q., Liu, Y., & Zhang, T. (2026) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s644860
Regulation of blood flow in subcutaneous adipose tissue
Sotorník, R. (2018) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
kashmoola, Q. M., Shafi, S. K. M., Haboobi, N. H. A., Fikry, M. A., Albastaki, F. A., Khalid, N. W., Ahmed, M. M. A., Pinheiro, A. J., Masoud, A. E. A., & Tahmaz, G. A. A. (2025) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/0cqhb709
Metadata
- Authors
- Asmar, M., Simonsen, L., Asmar, A., Holst, J. J., Dela, F., & Bülow, J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Asmar, Meena
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-08
- Volume
- 101
- Issue
- 8
- Pages
- 3155-3162
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2411975823
- Cited by
- 61
- References
- 39
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 13 · 2023: 3 · 2022: 8 · 2021: 5 · 2020: 1 · 2019: 7 · 2018: 3 · 2017: 3 · 2016: 1
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucose-dependent insulinotropic polypeptide, insulin, adipose tissue blood flow, triglyceride clearance, adipose tissue metabolism, C-peptide, free fatty acid release, glycerol release, subcutaneous abdominal fat, hyperinsulinemia, octreotide, Fick's principle, lean subjects, hyperglycemic clamp
- MeSH terms
- Adipose Tissue, Adult, Drug Synergism, Gastric Inhibitory Polypeptide, Humans, Insulin, Male, Regional Blood Flow, Vasoconstriction, Vasoconstrictor Agents, Glucose Clamp Technique, Cross-Over Studies, Subcutaneous Fat, Abdominal, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.